Arch Therapeutics Reports on Current Activities
30 Juli 2013 - 3:00PM
Marketwired
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch"
or the "Company"), a life science company and developer of AC5™, a
novel product aimed at controlling bleeding and fluid loss in order
to provide faster and safer surgical and interventional care, is
pleased to provide a summary of current events.
Arch Therapeutics is developing products that make surgery and
interventional care faster and safer by utilizing a novel approach
to stop bleeding (referenced as "hemostasis"), control leaking
(referenced as "sealant"), and provide other advantages during
surgery and trauma care. AC5™ is based on a self-assembling peptide
solution that creates a physical, mechanical barrier, which could
be applied to bleeding organs or wounds to seal leaking blood and
other fluids.
To date, we have devoted much of the work on our core technology
to selecting the lead product composition, conducting initial
safety and efficacy tests, developing reproducible and reliable
analytical and manufacturing methods, and scale-up. We have also
focused on developing relevant intellectual property rights via
filing several patent applications in multiple jurisdictions for
self-assembling peptides and methods of use thereof, all of which
are pending. Much of this pre-clinical work is a necessary
pre-requisite to the clinical-regulatory program, which we are
currently designing.
The results of early data from preclinical tests have shown that
AC5™ achieves hemostasis quickly and effectively. AC5™ can be
directly applied as a liquid or sprayed, making it user-friendly
and able to conform to irregular wound geometry, and is not sticky
or glue-like, making it ideal for use in the setting of minimally
invasive laparoscopic surgeries. Further, AC5™ is transparent,
which should make it easier for surgeons or other healthcare
providers to maintain a clear field of vision during a surgical
procedure and prophylactically stop bleeding as it starts, which we
call Crystal Clear Surgery™.
Preclinical testing to date has been conducted in a number of
settings. One of the co-founders of our technology, Dr. Rutledge
Ellis-Behnke, performed a significant portion of the preclinical
experimentation at major academic institutions in Massachusetts
(2001-2005) and Hong Kong (2004-2009). Some of the most significant
findings from Dr. Ellis-Behnke's studies have been published.
Importantly, we have further engaged both academic and private
third party facilities in the United States, including in
Massachusetts, and in Europe, including a successful collaboration
with several parties at the National University of Ireland and the
Royal College of Surgeons in Ireland, in order to further advance
the technology to its current state.
Company CEO, Dr. Terrence Norchi comments, "In the preclinical
tests conducted to date, AC5™ has demonstrated improved average
time to hemostasis ('TTH') during a range of surgical procedures
compared to TTH when using a control substance, a saline control
substance, a control peptide, and a cautery control substance
during those same procedures. The results of those tests have shown
a TTH of under 15 seconds when AC5™ was applied, compared to a TTH
ranging from 80 to 300 seconds when various control substances were
applied, depending on the nature of the control substance and
procedure performed. To date, we have noted no ill effects or other
adverse consequences. We believe that the peptide degrades into the
naturally occurring amino acids from which it was originally
synthesized, which are molecules that already exist in large
quantities in the body. Our plans in the near-term are to focus our
efforts on the development of AC5™ by pursuing additional
preclinical studies and preparing for future clinical trials."
Additional details regarding Arch Therapeutics, Inc., its
business, agreements and related matters are filed as part of the
Company's continuous public disclosure as a reporting issuer under
the Securities Exchange Act of 1934 filed with the Securities and
Exchange Commission ("SEC"), and are available at the SEC's website
at www.sec.gov. For more information, visit our website at
www.archtherapeutics.com.
About Arch Therapeutics, Inc. (OTCQB:
ARTH) Arch Therapeutics, Inc. (OTCQB: ARTH) is a medical device
company developing a novel approach to stop bleeding (hemostasis)
and control leaking (sealant) during surgery and trauma care.
Arch's goal is to develop and commercialize products based on our
innovative technology platform that make surgery and interventional
care faster and safer for patients. Arch's flagship development
stage product candidate known as AC5™ is being designed to
elegantly achieve hemostasis in minimally invasive and open
surgical procedures. Find out more at www.archtherapeutics.com.
Notice Regarding Forward-Looking
Statements This news release contains "forward-looking
statements" as that term is defined in Section 27(a) of the
Securities Act of 1933, as amended, and Section 21(e) of the
Securities Exchange Act of 1934, as amended. Statements in this
press release that are not purely historical are forward-looking
statements and include any statements regarding beliefs, plans,
expectations or intentions regarding the future. Such
forward-looking statements include, among other things, references
to novel technologies and methods, our business and product
development plans and projections, or market information. Actual
results could differ from those projected in any forward-looking
statements due to numerous factors. Such factors include, among
others, the inherent uncertainties associated with developing new
products or technologies and operating as a development stage
company, our ability to retain important members of our management
team and attract other qualified personnel, our ability to raise
the additional funding we will need to continue to pursue our
business and product development plans, our ability to develop and
commercialize products based on our technology platform, and market
conditions. These forward-looking statements are made as of the
date of this news release, and we assume no obligation to update
the forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements. Although we believe that any beliefs, plans,
expectations and intentions contained in this press release are
reasonable, there can be no assurance that any such beliefs, plans,
expectations or intentions will prove to be accurate. Investors
should consult all of the information set forth herein and should
also refer to the risk factors disclosure outlined in the reports
and other documents we file with the SEC, available at
www.sec.gov.
On Behalf of the Board,
Terrence W. Norchi, MD. Arch Therapeutics, Inc.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: ARTH Investor Relations Toll Free:
+1-855-340-ARTH (2784) (US and Canada) Email:
investors@archtherapeutics.com Website:
www.archtherapeutics.com
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Jul 2023 bis Jul 2024